RxDoctor Payments DataLook up a doctor →

Kelsie Cato, PA

Medical · Raleigh, NCNPI 1669706768

Payments from drug & device makers

$14,896in general payments, 2019–2025

Across 654 payments — averaging $22.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Averitas Pharma Inc.$1K
  • Teva Pharmaceuticals USA, Inc.$875
  • Lundbeck LLC$787
  • Pfizer$738
  • UCB, Inc.$731
  • plus $7K from 42 others

What the payments were for

  • Consulting fees$4503%
  • Food & beverage$14,44697%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,896 in reported general payments places this provider in the 95th percentile of 878 medical providers in North Carolina.

See all medical providers in North Carolina

Medicare billing

Part B allowed, 2024
$66,378
Medicare patients
314
Services billed
4,410

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Avonex (4 Pack)Interferon Beta-1a14$114,416
OxycontinOxycodone Hcl62$64,753
Buprenorphine204$57,782
Emgality PenGalcanezumab-Gnlm59$42,708
NucyntaTapentadol Hcl24$35,990
Nurtec OdtRimegepant Sulfate29$31,907
Fentanyl204$30,155
Aimovig AutoinjectorErenumab-Aooe39$28,324
BelbucaBuprenorphine Hcl37$24,879
Ajovy AutoinjectorFremanezumab-Vfrm22$21,726
QuliptaAtogepant12$12,803
UbrelvyUbrogepant11$12,223
SavellaMilnacipran Hcl12$12,179
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen442$11,428
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen423$11,133

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenAvonex (4 Pack)$79$114,41614 claims
Collegium Pharmaceutical, Inc.Nucynta, Belbuca$575$60,86961 claims
AbbVieQulipta, Ubrelvy, Savella$3,382$37,20535 claims
PfizerNurtec Odt$738$31,90729 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 878 medical providers in North Carolina.

Other medical in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →